Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears

finance.yahoo.com · 2026-09-10

Jim Cramer called Medtronic plc (NYSE:MDT) a “quandary” on the September 8 episode of Mad Money, as he said: At the same time, there’s some tremendous healthcare companies in bull market mode… Here’s one that’s a quandary, Medtronic. Medtronic, the medical device company, shocked us with a big upside surprise and a major increase in […]

TickrTrends take: Medtronic faces an interesting valuation inflection point as it navigates simultaneous acceleration in growth and a strategic exit from its diabetes business. TickrTrends currently assesses MDT as fairly valued, suggesting the market has already priced in near-term catalysts from the growth acceleration, leaving limited upside from current levels unless the company demonstrates sustained momentum beyond analyst expectations. Investors focused on valuation should monitor whether the diabetes exit generates meaningful capital for shareholder returns or debt reduction, as this could materially shift the fair value assessment if deployment decisions prove accretive to long-term earnings power.

Read the full story at finance.yahoo.com →